

**Supplementary Table 2.** Subgroup analyses for the risk of total stroke by baseline hemoglobin A1c in patients excluding those who died during the follow-up

Variable	Hemoglobin A1c (%)						P for trend
	<6.0	6.0–6.9	7.0–7.9	8.0–8.9	9.0–9.9	≥10	
<b>Baseline hemoglobin A1c level</b>							
No. of patients	10,648	24,385	12,522	6,292	3,701	7,392	
No. of cases	1,131	2,501	1,478	762	419	755	
Person-years	38,309	95,042	50,694	24,838	14,337	27,169	
Age-and sex-adjustment	1.10 (1.03–1.18)	1.00	1.18 (1.11–1.26)	1.35 (1.25–1.47)	1.44 (1.30–1.60)	1.59 (1.47–1.73)	<0.001
Multivariable adjustment	1.08 (1.01–1.11)	1.00	1.13 (1.05–1.20)	1.22 (1.12–1.33)	1.25 (1.13–1.39)	1.36 (1.24–1.38)	<0.001
<b>Mean follow-up hemoglobin A1c level</b>							
No. of patients	8,153	21,580	21,841	6,595	3,400	3,371	
No. of cases	1,021	2,269	2,155	800	410	391	
Person-years	30,428	85,219	81,526	26,676	13,579	12,959	
Age-and sex-adjustment	1.21 (1.12–1.30)	1.00	1.07 (1.01–1.13)	1.38 (1.27–1.50)	1.61 (1.45–1.79)	1.85 (1.65–2.06)	<0.001
Multivariable adjustment	1.14 (1.06–1.24)	1.00	1.05 (1.00–1.11)	1.21 (1.11–1.32)	1.40 (1.26–1.56)	1.51 (1.35–1.69)	<0.001

Values are presented as hazard ratio (95% confidence interval) unless otherwise indicated. Multivariable adjustment included age, sex, race, body mass index, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, estimated glomerular filtration rate, smoking, insurance type, use of antihypertensive drugs, use of glucose lowering drugs, use of lipid-lowering drugs, use of antiplatelet or anticoagulant drugs, and presence of atrial fibrillation.